Worth reading
40Recurring
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
501200
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of new shares as restricted stock compensation
Who receives how much501,200Shares
501,200 shares (new shares)
Directors of the Company (excluding directors who are Audit and Supervisory Committee members and outside directors)2 / 226,500 shares
Employees of the Company15 / 197,000 shares
Directors of 日本革新創薬株式会社 (excluding outside directors)3 / 77,700 shares
The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.
¥94 per share
Total issue value
¥47,112,800
Categories and Number of Persons Covered
Category Directors of the Company (excluding directors who are Audit and Supervisory Committee members and outside directors) / Number of Employees 2 / Number of allocated shares 226,500 shares, Category Employees of the Company / Number of Employees 15 / Number of allocated shares 197,000 shares, Category Directors of 日本革新創薬株式会社 (excluding outside directors) / Number of Employees 3 / Number of allocated shares 77,700 shares
Payment date
14 May 2026
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of new shares as restricted stock compensation |
| Number of shares to be issued or disposed of | 501,200 shares (new shares) |
| Issue price and disposal price | ¥94 per share |
| Total issue value | ¥47,112,800 |
| Payment date | 14 May 2026 |
| Intended allottee | Name Directors of the Company (excluding directors who are Audit and Supervisory Committee members and outside directors) / Number of Employees 2 / Number of Shares 226,500 shares, Name Employees of the Company / Number of Employees 15 / Number of Shares 197,000 shares, Name Directors of 日本革新創薬株式会社 (excluding outside directors) / Number of Employees 3 / Number of Shares 77,700 shares |
| Categories and Number of Persons Covered | Category Directors of the Company (excluding directors who are Audit and Supervisory Committee members and outside directors) / Number of Employees 2 / Number of allocated shares 226,500 shares, Category Employees of the Company / Number of Employees 15 / Number of allocated shares 197,000 shares, Category Directors of 日本革新創薬株式会社 (excluding outside directors) / Number of Employees 3 / Number of allocated shares 77,700 shares |
Items this document does not state (21)
Amount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The payment procedures for the issuance of new shares as restricted stock compensation, resolved on 17 April 2026, have been completed.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.